

Terumo Revises the First-Half and Full-Year Results Forecast for FY2018

TOKYO, JAPAN – August 8, 2018 – Terumo Corporation (TSE: 4543) today announced that it revised the first-half and full-year results forecast for the year ending March, 2019 (FY2018).

1. First-half results forecast for FY2018 (From April 1 to September 30, 2018)

	Revenue (Million yen)	Adjusted operating profit (Million yen)	Operating profit (Million yen)	Profit for the year attributable to the owners of the parent (Million yen)	Earnings per share (Yen)
Prior forecast	293,000	61,500	54,500	39,500	111.64
Revised forecast	282,000	55,000	48,000	34,500	96.30
Change in amount	-11,000	-6,500	-6,500	-5,000	-
Rate of change	-3.8%	-10.6%	-11.9%	-12.7%	-
(Reference) Results for the prior fiscal year*	284,610	64,823	57,175	41,146	116.90

* The results for the prior fiscal year have not yet got audited, because Terumo adopted IFRS since the full-year results for the fiscal year ended March 31, 2018.

2. Full-year results forecast for FY2018 (From April 1, 2018 to March 31, 2019)

	Revenue (Million yen)	Adjusted operating profit (Million yen)	Operating profit (Million yen)	Profit for the year attributable to the owners of the parent (Million yen)	Earnings per share (Yen)
Prior forecast	608,000	128,500	114,500	83,500	235.99
Revised forecast	597,000	122,000	108,000	78,500	218.52
Change in amount	-11,000	-6,500	-6,500	-5,000	-
Rate of change	-1.8%	-5.1%	-5.7%	-6.0%	-
(Reference) Results for the prior fiscal year	587,775	124,929	108,552	91,295	259.12

3. Reasons for the revision

As outlined in the “Terumo Announces Shipping Delays for Products from Ashitaka Factory” announced on July 4, Terumo had shipping delays for certain cardiovascular products from its Ashitaka Factory in Japan. The impact caused Terumo to revise the first-half and full-year results forecast.

About Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with over \$5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

Disclaimer

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.

###